Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

The expiration date of the key patent for guselkumab?
Allergan's patent for latisse expired?
Patent tenofovir alafenamide gilead?
Mebendazole ingredients?
Somatuline generic name?

Average weight loss on mounjaro?

See the DrugPatentWatch profile for mounjaro

Average weight loss reported in clinical studies of Mounjaro® (tirzepatide)

Study (phase 3) Dose Treatment duration Mean weight loss (kg) Mean percentage weight loss*
SURPASS‑2 (type 2 DM, 68 weeks) 5 mg 68 weeks ≈ 6.8 kg ≈ 5.8 %
SURPASS‑2 10 mg 68 weeks ≈ 10.7 kg ≈ 9.0 %
SURPASS‑2 15 mg 68 weeks ≈ 13.4 kg ≈ 11.6 %
SURPASS‑3 (type 2 DM, 68 weeks) 10 mg 68 weeks ≈ 9.6 kg ≈ 8.4 %
SURPASS‑3 15 mg 68 weeks ≈ 12.2 kg ≈ 10.7 %
Real‑world post‑marketing data (varied populations, 12–24 weeks) 10–15 mg 12–24 weeks ≈ 3–4 kg ≈ 3–5 %

*Percentage weight loss is calculated from baseline weight. The actual number varies by individual factors such as baseline BMI, diet, exercise, and adherence to the medication schedule.

Key take‑aways

Point Detail
Dose matters Higher doses (15 mg) consistently produce ~10–12 % weight loss over 68 weeks, while the 10 mg dose gives ~6–9 %.
Time matters Most of the weight loss occurs in the first 12–20 weeks; gains plateau thereafter.
Population Data above come from patients with type 2 diabetes (SURPASS trials). Real‑world studies in non‑diabetic adults show comparable or slightly lower reductions.
Comparison to Wegovy® Wegovy (tirzepatide 2.4 mg weekly) achieves ~15 % weight loss over 68 weeks in obese patients without diabetes. Mounjaro’s dosing schedule and FDA approval target diabetes management, not obesity, but the pharmacologic effect is similar.
Clinical significance A 10 % weight loss typically reduces cardiovascular risk, improves glycemic control, and lowers blood pressure and lipid levels.

What you should know before using Mounjaro for weight loss

  1. FDA approval – Mounjaro is approved for type 2 diabetes. It is not yet FDA‑approved specifically for weight management (Wegovy® is the obesity indication).
  2. Side‑effects – The most common adverse events are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These usually diminish after the first few weeks.
  3. Lifestyle support – Weight‑loss outcomes are maximized when combined with a calorie‑restricted diet and regular physical activity. The drug is not a “quick fix” on its own.
  4. Monitoring – Regular follow‑up with your healthcare provider is essential to adjust dose, watch for side‑effects, and assess cardiovascular and metabolic markers.
  5. Individual variability – Some people may lose more or less than the averages listed above. Genetic factors, age, sex, baseline weight, and adherence all influence results.

Bottom line

  • On average, patients taking the 15 mg dose of Mounjaro lose about 11–12 % of their baseline weight after 68 weeks (≈ 13–14 kg for a 120‑kg person).
  • The 10 mg dose yields roughly 8–9 % weight loss over the same period (≈ 9–11 kg).
  • These numbers come from rigorous phase‑3 trials and are supported by post‑marketing data.

If you’re considering Mounjaro for weight loss, discuss with a qualified clinician to confirm suitability, appropriate dosing, and a comprehensive plan that includes diet, exercise, and routine monitoring.



Other Questions About Mounjaro :

When can generic for mounjaro be made? Patente mounjaro us? Does mounjaro help sugar? What is the generic version of mounjaro? Mounjaro nhs pharmacuetical companies patent? How long does it take for mounjaro to start working? Quando expira a patente do mounjaro?